Here Is What You Need To Know Before Investing In Anbio Biotechnology (NNNN)

Anbio Biotechnology (NASDAQ:NNNN) is one of the 13 Best German Stocks to Invest in Now. The company is engaged in the development of medical technology and the provision of in vitro diagnostics products.

Here Is What You Need To Know Before Investing In Anbio Biotechnology (NNNN)

A scientist in a lab conducting research on cell-based therapeutics and biotechnology.

It was incorporated in 2021 and is based in Frankfurt. Anbio Biotechnology (NASDAQ:NNNN) had its initial public offering in February this year on the NASDAQ Global Market, with shares trading under the ticker ‘NNNN’.

The company announced receiving $8 million in aggregate gross proceeds from the offerings, which it intends to use for sales growth, expansion of the distribution network in selected markets, research & development, and other corporate purposes.

Anbio Biotechnology (NASDAQ:NNNN)’s NASDAQ debut has garnered strong investor interest, resulting in a nearly 600% surge from its IPO price of $5. The company is also currently pivoting from pandemic tests and is expanding into oncology, cardiovascular, and infectious diseases.

However, still a major chunk of Anbio Biotechnology (NASDAQ:NNNN)’s revenue comes from COVID-related in vitro diagnostics products, which could become a significant headwind in the short run for the company with the pandemic receding.

While we acknowledge the risk and potential of NNNN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NNNN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy and 13 Best Big Name Stocks to Buy Now.

Disclosure: None.